Research Center of Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.02067-19.
The effects of multiple-dose administration of tenofovir disoproxil fumarate (TDF) on the pharmacokinetics of morinidazole (MOR) were compared in healthy subjects. MOR exposure was similar, with an area under the curve from 0 h to infinity (AUC) treatment ratio for MOR+TDF/MOR of 1.01 (90% confidence interval, 0.97 to 1.06). No relevant differences were observed regarding plasma exposure of metabolites. Renal clearances of MOR and its metabolites were not affected by TDF. No unexpected safety or tolerability issues were observed.
在健康受试者中比较了富马酸替诺福韦二吡呋酯（TDF）多次给药对吗啉硝唑（MOR）药代动力学的影响。MOR 暴露相似，MOR+TDF/MOR 的曲线下面积从 0 小时到无穷大（AUC）比值为 1.01（90%置信区间，0.97 至 1.06）。未观察到与代谢物血浆暴露相关的任何显著差异。TDF 不影响 MOR 及其代谢物的肾清除率。未观察到意外的安全性或耐受性问题。
